Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $1.9 million, a decrease from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to a U.S. government shutdown [9][10] - Gross profit for Q4 2025 was $0.3 million (14.9% of revenue), compared to $0.9 million (15.5% in Q4 2024) [9][10] - Full year 2025 revenue was $17 million, down from $20.2 million in 2024, attributed mainly to the U.S. government shutdown and lower product sales [10][11] - Net loss for 2025 was $23.9 million ($2.10 per share), an improvement from a net loss of $30.2 million ($3.03 per share) in 2024 [12] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2025 were $4.5 million, up from $3 million in Q4 2024, reflecting ongoing investment in the EscharEx VALUE phase 3 study [10] - SG&A expenses for Q4 2025 totaled $3.6 million, down from $4 million in the same period last year, mainly due to lower marketing and share-based compensation expenses [10] - The expanded manufacturing facility for NexoBrid is now operational, increasing production capacity sixfold to meet growing global demand [6][8] Market Data and Key Metrics Changes - Enrollment in the global phase 3 VALUE study for EscharEx is ongoing, targeting 216 patients across approximately 40 sites in the U.S. and Europe, with completion expected by year-end 2026 [5][6] - NexoBrid is being utilized across more than 70 burn centers in the U.S., representing the majority of Vericel's target accounts [6][8] Company Strategy and Development Direction - The company aims to advance EscharEx towards pivotal milestones and secure regulatory approvals for the expanded manufacturing facility, focusing on long-term value creation [15] - MediWound is expanding the EscharEx clinical program to include diabetic foot ulcers and pressure ulcers, aligning with both the FDA and EMA [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating ongoing geopolitical challenges and emphasized a focus on clinical milestones and commercial objectives [4] - The company reaffirmed its revenue guidance of $24 million-$26 million for 2026, with expectations of continued support from BARDA and the U.S. Department of Defense [14][15] Other Important Information - The company completed a $30 million registered direct offering and $3.5 million from Series A warrant exercises, strengthening its balance sheet [12][13] - The company plans to prioritize support for national preparedness initiatives, including stockpiling and collaboration with military and emergency response systems [8] Q&A Session Summary Question: Can you review the timing of MediWound filling demand for NexoBrid over the next 12-24 months? - The expanded manufacturing facility is operational, with a sixfold increase in capacity, and regulatory approvals are expected in late 2026, which will allow for market release [18] Question: Can you discuss the pressure ulcer trial and its potential market size? - The pressure ulcer indication is expected to be significant, potentially representing a third of the business, but further market research is needed to quantify the opportunity [26][27] Question: How much of the 2026 revenue guidance is based on new contracts versus existing awards? - The revenue guidance includes potential contributions from BARDA and the U.S. Department of Defense, but specific splits were not disclosed [30][33] Question: What is the status of the head-to-head study? - The head-to-head study is planned to start around mid-2026, which will help determine the pricing of EscharEx [70][71] Question: Will the interim analysis for the VALUE study be completed by year-end? - The interim analysis is expected to be completed by year-end, with no specific enrollment numbers shared to protect study integrity [72][77]